Tomorrow.Bio, a Berlin-based cryonics company, has successfully completed the first close of a €5M equity funding round. This funding will support its efforts to preserve individuals after death using liquid nitrogen until future technological advancements can revive them. Co-led by Blast.Club and TruVenturo, the investment round aims to enhance Tomorrow.Bio's capabilities, particularly in expanding to the US and advancing research on preservation techniques. Both Nils Regge and Anthony Bourbon commend the company's innovative approach, arguing it has the potential to dramatically change perceptions of life and death while introducing significant business opportunities.
Nils Regge emphasizes that Tomorrow.Bio is at the forefront of longevity, supporting impactful moonshots that could extend life spans and create significant business opportunities.
Anthony Bourbon remarks on Tomorrow.Bio's technology that is changing perceptions of life and death, noting how the founders' vision positions the company for future medicine.
Dr. Emil Kendziorra expresses excitement over securing visionary investors for long-term goals including US expansion and advancing preservation technology.
Collection
[
|
...
]